Cardiovascular Effects of Relaxin-2: Therapeutic Potential and Future Perspectives

Overview

Journal Clin Res Cardiol

Specialty Cardiology & Vascular Diseases

Date 2023 Sep 18

PMID 37721595

Authors

Nisia Almeida-Pinto

Thomas Bernd Dschietzig

Carmen Bras-Silva

Rui Adao

Affiliations

Soon will be listed here.

Abstract

The hormone relaxin-2 has emerged as a promising player in regulating the physiology of the cardiovascular system. Through binding to the relaxin family peptide receptor 1 (RXFP1), this hormone elicits multiple physiological responses including vasodilation induction, reduction of inflammation and oxidative stress, and angiogenesis stimulation. The role of relaxin-2, or its recombinant human form known as serelaxin, has been investigated in preclinical and clinical studies as a potential therapy for cardiovascular diseases, especially heart failure, whose current therapy is still unoptimized. However, evidence from past clinical trials has been inconsistent and further research is needed to fully understand the potential applications of relaxin-2. This review provides an overview of serelaxin use in clinical trials and discusses future directions in the development of relaxin-2 mimetics, which may offer new therapeutic options for patients with heart failure.

Citing Articles

Seleno-relaxin analogues: effect of internal and external diselenide bonds on the foldability and a fibrosis-related factor of endometriotic stromal cells.

Satoh Y, Ono Y, Takahashi R, Katayama H, Iwaoka M, Yoshino O RSC Chem Biol. 2024; 5(8):729-737.

PMID: 39092438 PMC: 11289879. DOI: 10.1039/d4cb00095a.

References

Jakubauskiene L, Jakubauskas M, Leber B, Strupas K, Stiegler P, Schemmer P . Relaxin Positively Influences Ischemia-Reperfusion Injury in Solid Organ Transplantation: A Comprehensive Review. Int J Mol Sci. 2020; 21(2). PMC: 7013572. DOI: 10.3390/ijms21020631. View

Valle Raleigh J, Mauro A, Devarakonda T, Marchetti C, He J, Kim E . Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism. Cardiovasc Res. 2017; 113(6):609-619. DOI: 10.1093/cvr/cvw246. View

Martin B, Romero G, Salama G . Cardioprotective actions of relaxin. Mol Cell Endocrinol. 2019; 487:45-53. DOI: 10.1016/j.mce.2018.12.016. View

Severino P, DAmato A, Prosperi S, Myftari V, Canuti E, Labbro Francia A . Heart Failure Pharmacological Management: Gaps and Current Perspectives. J Clin Med. 2023; 12(3). PMC: 9917449. DOI: 10.3390/jcm12031020. View

Gheorghiade M, Sopko G, De Luca L, Velazquez E, Parker J, Binkley P . Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006; 114(11):1202-13. DOI: 10.1161/CIRCULATIONAHA.106.623199. View

Gheorghiade M, Abraham W, Albert N, Greenberg B, OConnor C, She L . Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006; 296(18):2217-26. DOI: 10.1001/jama.296.18.2217. View

Clara Martins R, Pintalhao M, Leite-Moreira A, Castro-Chaves P . Relaxin and the Cardiovascular System: from Basic Science to Clinical Practice. Curr Mol Med. 2019; 20(3):167-184. DOI: 10.2174/1566524019666191023121607. View

Feiteng C, Lei C, Deng L, Chaoliang X, Zijie X, Yi S . Relaxin inhibits renal fibrosis and the epithelial-to-mesenchymal transition via the Wnt/β-catenin signaling pathway. Ren Fail. 2022; 44(1):513-524. PMC: 8942541. DOI: 10.1080/0886022X.2022.2044351. View

Metra M, Teerlink J, Cotter G, Davison B, Felker G, Filippatos G . Effects of Serelaxin in Patients with Acute Heart Failure. N Engl J Med. 2019; 381(8):716-726. DOI: 10.1056/NEJMoa1801291. View

10.

Halls M, Bathgate R, Sutton S, Dschietzig T, Summers R . International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides. Pharmacol Rev. 2015; 67(2):389-440. PMC: 4394689. DOI: 10.1124/pr.114.009472. View

11.

Ferrari R, Bueno H, Chioncel O, Cleland J, Stough W, Lettino M . Acute heart failure: lessons learned, roads ahead. Eur J Heart Fail. 2018; 20(5):842-850. DOI: 10.1002/ejhf.1169. View

12.

Jagathesan R, Rosen S, Foale R, Camici P, Picano E . Effects of long-term oral dipyridamole treatment on coronary microcirculatory function in patients with chronic stable angina: A substudy of the persantine in stable angina (PISA) study. J Cardiovasc Pharmacol. 2006; 48(3):110-6. DOI: 10.1097/01.fjc.0000245404.20922.9f. View

13.

Sarwar M, Du X, Dschietzig T, Summers R . The actions of relaxin on the human cardiovascular system. Br J Pharmacol. 2016; 174(10):933-949. PMC: 5406304. DOI: 10.1111/bph.13523. View

14.

Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster F, Baumann G . The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 2001; 15(12):2187-95. DOI: 10.1096/fj.01-0070com. View

15.

Miro O, Gil V, Muller C, Mebazaa A, Bueno H, Martin-Sanchez F . How does a clinical trial fit into the real world? The RELAX-AHF study population into the EAHFE registry. Clin Res Cardiol. 2015; 104(10):850-60. DOI: 10.1007/s00392-015-0854-z. View

16.

Samuel C, Bennett R . Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directions. Biochem Pharmacol. 2021; 197:114884. DOI: 10.1016/j.bcp.2021.114884. View

17.

Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J, Richter C . First clinical experience with intravenous recombinant human relaxin in compensated heart failure. Ann N Y Acad Sci. 2009; 1160:387-92. DOI: 10.1111/j.1749-6632.2008.03819.x. View

18.

Du X, Bathgate R, Samuel C, Dart A, Summers R . Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol. 2009; 7(1):48-58. DOI: 10.1038/nrcardio.2009.198. View

19.

Corcoran D, Radjenovic A, Mordi I, Nazir S, Wilson S, Hinder M . Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial. Cardiovasc Res. 2020; 117(1):320-329. PMC: 7797213. DOI: 10.1093/cvr/cvz345. View

20.

Teerlink J, Davison B, Cotter G, Maggioni A, Sato N, Chioncel O . Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. Eur J Heart Fail. 2019; 22(2):315-329. DOI: 10.1002/ejhf.1692. View